EnGen Bio Presentation: 3:15 p.m., Monday, September 13, 2010, on the Healthcare Track
Dyadic Presentation: 8:20 a.m., Wednesday, September 15, 2010, on the Cleantech Track
JUPITER, Fla., September 8, 2010 – Dyadic International, Inc. (“Dyadic”) (Pink Sheets: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced that its President and Chief Executive Officer, Mark Emalfarb, will present at the
Rodman & Renshaw Annual Global Investment Conference at The Palace Hotel in New York City on Wednesday, September 15, 2010 at 8:20 a.m. on the Cleantech track.
Earlier in the week, on Monday, September 13th at 3:15 p.m. on the Healthcare track, the Chief Executive Officer of EnGen Bio, Inc., Mark R. Alfenito, Ph.D., will also be presenting. As previously announced, Dyadic and EnGen Bio have entered into a non-binding term sheet for a potential outlicense, on an exclusive worldwide basis, of Dyadic’s C1 platform technology for biopharmaceutical drug applications.
The conference will include a series of one-on- one meetings with institutional investors. Investors interested in scheduling a meeting with Dyadic or in being added to Dyadic’s email list may do so by contacting Heidi Zosiak at Dyadic firstname.lastname@example.org. Meetings may also be scheduled by contacting a Rodman & Renshaw representative directly.
Webcasts of both the Dyadic and EnGen Bio presentations will be held live and can be accessed athttp://www.wsw.com/webcast/rrshq18/dyai.pk/ and http://www.wsw.com/webcast/rrshq18/engen/, respectively.
Following the live presentations, an audio and slide archive of both presentations will be available on Dyadic’s website atwww.dyadic.com.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries.
CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release are forward- looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.
Dyadic International, Inc.
Adam J. Morgan
Vice President General Counsel & Business Development